Status:
COMPLETED
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
Lead Sponsor:
NEAT ID Foundation
Collaborating Sponsors:
Gilead Sciences
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases from up to 20 participating study sites who meet all eligibility criteria will be included in the analysis....
Eligibility Criteria
Inclusion
- All Adult participants with COVID-19 confirmed by PCR who meet the following criteria:
- Hospitalised after August 31st,2020
- Receivedat least one dose of Remdesivir(RDV)at anytime during hospitalisation
Exclusion
- Received Remdesivir as part of a clinical trial, compassionate use or expanded access program
- Received Remdesivir prior to this admission at any other health facility than the research sites and whose health records are available.
Key Trial Info
Start Date :
February 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
451 Patients enrolled
Trial Details
Trial ID
NCT04847622
Start Date
February 12 2021
End Date
April 30 2021
Last Update
November 29 2024
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France
2
Hospital Lariboisiere
Paris, France, 75010
3
Hopital Saint-Louis
Paris, France
4
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel